{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"PFS was planned to be assessed in Part 2. PFS was defined as the time from start of treatment until the first documented progressive disease (PD), as assessed by Investigator per IMWG 2016 guidelines for MM or Lugano 2014 guidelines for DLBCL or death due to any cause, whichever occurred first. Per IMWG response criteria, PD was defined as any 1 or more of the following criteria: a) increase of ≥25% from lowest confirmed value in either serum MP, serum MP increase ≥1 gram/deciliter (g/dL) if the lowest M-component was ≥5 g/dL or urine M-component, b) appearance of new lesion(s), ≥50% increase from nadir in SPD of \\>1 lesion, or ≥50% increase in the longest diameter of a previous lesion \\>1 centimeter (cm) in short axis.","groups":[{"description":"Participants with R/R MM with t(4;14) were planned to receive EZM0414 tablet at MTD orally QD in continuous 28-day cycles until consent withdrawal, unacceptable toxicity, disease progression or need for treatment prohibited on this study.","id":"OG000","title":"Part 2: Cohort 1: R/R MM With t(4;14)"},{"description":"Participants with R/R MM without t(4;14) were planned to receive EZM0414 tablet at MTD orally QD in continuous 28-day cycles until consent withdrawal, unacceptable toxicity, disease progression or need for treatment prohibited on this study.","id":"OG001","title":"Part 2: Cohort 2: R/R MM Without t(4;14)"},{"description":"Participants with R/R DLBCL were planned to receive EZM0414 tablet at MTD orally QD in continuous 28-day cycles until consent withdrawal, unacceptable toxicity, disease progression or need for treatment prohibited on this study.","id":"OG002","title":"Part 2: Cohort 3: R/R DLBCL"}],"populationDescription":"The study was terminated prior to completing Part 1 of the study. Part 2 was not started.","reportingStatus":"POSTED","timeFrame":"Tumour assessments were planned to be performed at Screening (within 28 days before start of study treatment) or Cycle 1 Day 1 (pre-dose) up to end of the study, approximately 23 months","title":"Part 2: Progression-free Survival (PFS)","type":"SECONDARY"}